Skip to content

Evaluation of the effect of Colchicine in the patients with Acute Coroanry Syndrome

Evaluation of the effect of Colchicine on incidence of Major Adverse Cardiac Events (MACE) in the patients with Acute Coronary Syndrome (ACS) during the first 6 months of Colchicine use

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20201117049420N1
Enrollment
240
Registered
2020-11-22
Start date
2019-09-23
Completion date
Unknown
Last updated
2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome. ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction

Interventions

Intervention 1: Intervention Group: This group will receive standard treatment of ACS plus 0.5 mg per day Colchicine for 6 months. Intervention 2: Control Group: This group will receive standard treat

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients who have completed the informed consent form Patients aged 40-70 years with history of chest pain who have undergone Coronary Angiography with the aim of medical treatment or who have undergone Total or Near Total Revascularization Whose information and follow ups are completed

Exclusion criteria

Exclusion criteria: 1. Patients with history of hypersensitivity to Colchicine 2. Patients with history of Moderate Renal Dysfunction (GFR 1.5 * ULN) 4. Patients with history of Thrombocytopenia and or Leukopenia 5. Pregnant patient, Lactating women, and women at risk of Pregnancy 6. Patients who are already taking Colchicine 7. Patients who have undergone CABG (Coronary Artery Bypass Grafting) 8. Patients with LVEF less than 30%

Design outcomes

Primary

MeasureTime frame
Hospitalization due to typical chest pain (Acute Coronary Syndrome). Timepoint: We will follow up all patients 7 days after discharge from the hospital and then monthly to assess Hospitalization due to typical chest pain (Acute Coronary Syndrome) by telephone. They will also be visited every two months. Method of measurement: Questioning the patient and the patient,s visitor; and reviewing the patient's documents.;All Cause Mortality. Timepoint: We will follow up all patients 7 days after discharge from the hospital and then monthly to assess mortality by telephone. They will also be visited every two months. Method of measurement: Questioning the patient and the patient,s visitor; and reviewing the patient's documents.;Stroke. Timepoint: We will follow up all patients 7 days after discharge from the hospital and then monthly to assess Stroke by telephone. They will also be visited every two months. Method of measurement: Questioning the patient and the patient,s visitor; and reviewing the patient's documents.;Decompensated Heart Failure. Timepoint: We will follow up all patients 7 days after discharge from the hospital and then monthly to assess Decompensated Heart Failure by telephone. They will also be visited every two months. Method of measurement: Questioning the patient and the patient,s visitor; and reviewing the patient's documents.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Akrami

Shiraz University of Medical Sciences

akrami.mi@gmail.com+98 71 3228 9696

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026